This study is currently recruiting patients.
Sponsored by National Cancer Institute (NCI).
This study will examine the safety and effectiveness of Campath-1H for treating patients with adult T-cell leukemia (ATL). ATL is caused by a virus called HTLV-1 that infects lymphocytes (white blood cells) called T-cells. Cancerous cells can be found not only in the blood, but also in the skin, lungs, lymph nodes, liver, bone, bone marrow, spleen, and meninges (tissues covering the brain). There are four categories of ATL, based on the aggressiveness of disease smoldering, chronic, lymphoma, and acute. Campath-1H is a monoclonal antibody that attaches to and kills normal and cancerous lymphocytes, including T cells. Although Campath-1H is an experimental drug for treating ATL, it is approved by the Food and Drug Administration for treating chronic lymphocytic leukemia.
Study ID Numbers: 030194; 03-C-0194
ClinicalTrials.gov Identifier: NCT00061048
COPYRIGHT 2005 Journal of Drugs in Dermatology
COPYRIGHT 2005 Gale Group